Baker Bros. Advisors LP
About Baker Bros. Advisors LP’s 13F portfolio
Baker Bros. Advisors LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Baker Bros. Advisors LP reported $20.0B across 84 US-listed positions (). Its largest position is Incyte Corporation (INCY) at 17% of the reported book, and its ten biggest holdings make up 73% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: INCY Incyte Corporation | — — | 17% | 30.8M | $3.5B |
| 2 | NASDAQ: ONC BeOne Medicines Ltd. | — — | 13% | 8.8M | $2.5B |
| 3 | NASDAQ: RVMD Revolution Medicines, Inc. | — — | 11% | 11.4M | $2.1B |
| 4 | NASDAQ: MDGL Madrigal Pharmaceuticals, Inc. | — — | 5.8% | 2.1M | $1.2B |
| 5 | NASDAQ: ACAD ACADIA Pharmaceuticals Inc. | — — | 5.4% | 42.9M | $1.1B |
| 6 | NASDAQ: KYMR Kymera Therapeutics, Inc. | — — | 5.0% | 8.7M | $992.7M |
| 7 | NASDAQ: INSM Insmed Incorporated | — — | 4.7% | 8.8M | $937.8M |
| 8 | NASDAQ: CELC Celcuity Inc. | — — | 4.2% | 7.9M | $828.2M |
| 9 | NASDAQ: KOD Kodiak Sciences Inc. | — — | 3.9% | 19.9M | $776.1M |
| 10 | NASDAQ: RYTM Rhythm Pharmaceuticals, Inc. | — — | 3.1% | 5.6M | $622.3M |
| 11 | NASDAQ: PRAX Praxis Precision Medicines, Inc. | — — | 2.9% | 1.8M | $587.0M |
| 12 | NASDAQ: ALKS Alkermes plc | — — | 2.6% | 10.0M | $524.6M |
| 13 | NASDAQ: SMMT Summit Therapeutics Inc. | — — | 2.4% | 32.8M | $477.7M |
| 14 | NASDAQ: GRAL GRAIL, Inc. | — — | 1.4% | 4.0M | $275.0M |
| 15 | NASDAQ: ABCL AbCellera Biologics Inc. | — — | 1.3% | 33.0M | $259.1M |
| 16 | NASDAQ: IMVT Immunovant, Inc. | — — | 1.0% | 5.4M | $209.4M |
| 17 | NASDAQ: IDYA IDEAYA Biosciences, Inc. | — — | 0.9% | 5.0M | $186.7M |
| 18 | NASDAQ: KNSA Kiniksa Pharmaceuticals International, plc | — — | 0.9% | 2.8M | $181.3M |
| 19 | NASDAQ: ROIV Roivant Sciences Ltd. | — — | 0.8% | 4.7M | $166.9M |
| 20 | NASDAQ: ARWR Arrowhead Pharmaceuticals, Inc. | — — | 0.8% | 2.0M | $162.4M |
| 21 | NASDAQ: IONS Ionis Pharmaceuticals, Inc. | — — | 0.8% | 2.0M | $162.4M |
| 22 | NASDAQ: EWTX Edgewise Therapeutics, Inc. | — — | 0.8% | 3.7M | $150.4M |
| 23 | NASDAQ: REPL Replimune Group, Inc. | — — | 0.6% | 11.0M | $122.3M |
| 24 | NASDAQ: NRIX Nurix Therapeutics, Inc. | — — | 0.6% | 4.7M | $113.0M |
| 25 | NASDAQ: STOK Stoke Therapeutics, Inc. | — — | 0.5% | 3.3M | $109.2M |
Showing 1–25 of 84 positions on this page reported in this 13F.
- Healthcare100%
- AddedINCYIncyte Corporation+0.1%$3.5B
- AddedONCBeOne Medicines Ltd.+0.0%$2.5B
- AddedRVMDRevolution Medicines, Inc.+19.8%$2.1B
- AddedMDGLMadrigal Pharmaceuticals, Inc.+0.1%$1.2B
- AddedACADACADIA Pharmaceuticals Inc.+0.0%$1.1B
- AddedINSMInsmed Incorporated+18.5%$937.8M
- AddedABCLAbCellera Biologics Inc.+9.0%$259.1M
- AddedIDYAIDEAYA Biosciences, Inc.+26.9%$186.7M
- AddedKNSAKiniksa Pharmaceuticals International, plc+0.3%$181.3M
- AddedDNLIDenali Therapeutics Inc.+0.1%$96.0M
- ReducedSMMTSummit Therapeutics Inc.−9.9%$477.7M
- ReducedIMVTImmunovant, Inc.−0.4%$209.4M
- ReducedROIVRoivant Sciences Ltd.−3.1%$166.9M
- ReducedEWTXEdgewise Therapeutics, Inc.−43.7%$150.4M
- ReducedIMTXImmatics N.V.−12.9%$96.3M
- ReducedJBIOJade Biosciences, Inc.−25.0%$27.3M
- ReducedCERSCerus Corporation−36.1%$18.7M
- SoldPHVSPharvaris N.V.−100%—
- SoldARGXargenx SE−100%—
- SoldCTNMContineum Therapeutics, Inc.−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | KOD Kodiak Sciences Inc. | 13D | 35.0% · 2 classes | 22.0M | Filed 30 SEP 2026 |
| 2 | PRLD Prelude Therapeutics Inc | 13D | 23.5% · 2 classes | 10.3M | Filed 13 JUN 2025 |
| 3 | SERA Sera Prognostics, Inc. | 13D | 16.1% | 5.5M | Filed 14 FEB 2025 |
| 4 | INCY Incyte Corp | 13D | 15.7% · 2 classes | 31.2M | Filed 10 FEB 2026 |
| 5 | REPL Replimune Group, Inc. | 13D | 14.3% · 2 classes | 11.0M | Filed 07 MAR 2025 |
| 6 | KYMR Kymera Therapeutics, Inc. | 13D | 10.9% | 8.7M | Filed 11 DEC 2025 |
| 7 | ABCL AbCellera Biologics Inc. | 13G | 10.8% | 33.0M | Filed 07 MAY 2026 |
| 8 | DBVT DBV Technologies S.A. | 13D | 10.0% | 25.6M | Filed 14 JAN 2026 |
| 9 | GLUE Monte Rosa Therapeutics, Inc. | 13G | 10.0% · 2 classes | 8.9M | Filed 15 MAY 2026 |
| 10 | CELC Celcuity Inc. | 13G | 10.0% · 2 classes | 4.9M | Filed 16 JUL 2026 |
| 11 | KALA KALA BIO, Inc. | 13G | 10.0% | 2.9M | Filed 17 FEB 2026 |
| 12 | IMTX Immatics N.V. | 13G | 9.9% | 12.1M | Filed 14 NOV 2025 |
| 13 | GRAL GRAIL, Inc. | 13G | 9.8% · 2 classes | 4.0M | Filed 15 MAY 2026 |
| 14 | RYTM Rhythm Pharmaceuticals, Inc. | 13G | 8.9% | 5.6M | Filed 15 MAY 2025 |
| 15 | BEIGF BeOne Medicines Ltd. | 13D | 7.8% | 115.9M | Filed 16 SEP 2026 |
| 16 | NRIX Nurix Therapeutics, Inc. | 13G | 7.2% | 7.5M | Filed 17 FEB 2026 |
| 17 | KNSA Kiniksa Pharmaceuticals International, plc | 13D | 7.0% | 3.3M | Filed 26 MAY 2026 |
| 18 | NGNE Neurogene Inc. | 13G | 7.0% | 992K | Filed 14 AUG 2025 |
| 19 | EWTX Edgewise Therapeutics, Inc. | 13G | 6.9% | 7.3M | Filed 14 AUG 2025 |
| 20 | PRAX Praxis Precision Medicines, Inc. | 13G | 6.3% | 1.8M | Filed 15 MAY 2026 |
| 21 | ALKS Alkermes plc. | 13G | 6.1% | 10.0M | Filed 17 FEB 2026 |
| 22 | STOK Stoke Therapeutics, Inc. | 13G | 5.8% | 3.3M | Filed 17 FEB 2026 |
| 23 | IDYA IDEAYA Biosciences, Inc. | 13G | 5.2% | 5.0M | Filed 14 AUG 2026 |
Showing all 23 disclosed stakes. 6 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Baker Bros. Advisors LP’s 13F portfolio
Baker Bros. Advisors LP’s $20.0B 13F book is spread across 84 reported positions and is highly concentrated — its ten largest positions alone are 73% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are INCY, ONC, RVMD, MDGL and ACAD, led by Incyte Corporation (INCY) at 17% of the portfolio. The heaviest sector exposure is Healthcare (100%).
What Baker Bros. Advisors LP changed last quarter
Between 2026-03-31 and Q2 2026, Baker Bros. Advisors LP was a net buyer: it opened 8 new positions and added to 16 more, while trimming 7 and closing 8 outright. Against a 84-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was Incyte Corporation (INCY), and its biggest reduction was Summit Therapeutics Inc. (SMMT).
What a 13F does and doesn’t reveal
A 13F captures only Baker Bros. Advisors LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Baker Bros. Advisors LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Baker Bros. Advisors LP's profile on this page is built directly from those filings.
How current is the 13F data on Baker Bros. Advisors LP's page?
It reflects Baker Bros. Advisors LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Baker Bros. Advisors LP files its next quarterly report, this page refreshes automatically.
Can I see Baker Bros. Advisors LP's complete list of holdings?
This page highlights Baker Bros. Advisors LP's largest positions rather than all 84 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Baker Bros. Advisors LP's filings.
Does a 13F show everything Baker Bros. Advisors LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Baker Bros. Advisors LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Baker Bros. Advisors LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

